Global Respiratory Partnerships Directory/Report 2021: Full Access to 850+ Deal Records – Deal Trends, Players & Financials – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The report “Global Respiratory Partnering 2010-2021: Deal Trends, Players and Financials” has been added to from ResearchAndMarkets.com offer.

The Global Respiratory Partnering 2010 to 2021 report provides comprehensive access to available offers and contract documents for over 850 respiratory offers.

Most transactions included in the report occur when a licensee obtains a right or option to license the product or technology from a licensor. More often than not these days, these agreements tend to be multi-component, including both collaborative R&D and an element of commercializing the results.

The report presents readers with comprehensive Respiratory Disease Agreement trends, key players, and major agreement values ​​to understand how, why, and under what conditions companies are currently entering into Respiratory Disease Agreements.

The report presents the values ​​of financial transaction terms for respiratory transactions, if any, a list by aggregate values, upfront payments, milestones and royalties allowing readers to analyze and compare the value of ongoing transactions.

In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of respiratory technologies and products.

The report includes offerings for the following indications: Allergic Rhinitis, Acute Respiratory Distress Syndrome, Asthma, Bronchitis, Chronic Obstructive Pulmonary Disease, Emphysema, Idiopathic Pulmonary Fibrosis, Occupational Lung Disease, Asbestosis, Coal Workers’ Pneumoconiosis, Hypersensitivity Pneumonitis, Silicosis , pneumonia, pulmonary arterial pneumonia. hypertension, pulmonary embolism, respiratory tract infection, sarcoidosis, sinusitis, shortness of breath, bronchospasm, chest pain, cough, nasal congestion, snoring, wheezing, as well as other respiratory indications.

Report scope

The Global Respiratory Partnership 2010 to 2021 includes:

• Trends in respiratory transactions in the biopharmaceutical industry since 2010

• Access to master, initial, milestone and royalty data

• Access to hundreds of contractual documents on respiratory contracts

• Full access to over 850 respiratory transaction records

• The main respiratory transactions by value since 2010

• Most active respiratory negotiators since 2010

In Global Respiratory Partnering 2010 to 2021, available offers and contracts are listed by:

• Face value

• Initial Payment Value

• Royalty rate value

• Stage of development at signing

• Offer component type

• Type of technology

• Specific therapeutic indication

The analysis of the actual contractual agreements makes it possible to evaluate the following elements:

• What specific rights are granted or optional?

• What is actually granted by the agreement to the partner company?

• What exclusivity is granted?

• What is the payment structure for the transaction?

• How are sales and payments audited?

• What is the duration of the agreement?

• How are the main terms of the agreement defined?

• How are IPRs managed and owned?

• Who is responsible for marketing?

• Who is responsible for development, supply and manufacturing?

• How are confidentiality and publication managed?

• How to settle disputes?

• Under what conditions can the agreement be terminated?

• What happens if the owner changes?

• What sub-licensing and sub-contracting arrangements have been agreed upon?

• What boilerplate clauses does the company insist on?

• What boilerplate clauses seem to differ from one partner to another or from one type of transaction to another?

• What jurisdiction does the company insist on for contract law?

Main topics covered:

Abstract

Chapter 1 Introduction

Chapter 2 – Trends in Respiratory Transactions

2.1. introduction

2.2. The respiratory partnership over the years

2.3. Respiratory partnership by transaction type

2.4. Respiratory partnership by industry sector

2.5. Respiratory partnership by developmental stage

2.6. Respiratory partnership by type of technology

2.7. Respiratory partnership by therapeutic indication

Chapter 3 -Financial conditions of the respiratory partnership

3.1. introduction

3.2. Financial Terms Disclosed for Respiratory Partnership

3.3. Key values ​​of the respiratory partnership

3.4. Respiratory Agreement Upfront Payments

3.5. Respiratory Agreement Milestone Payments

3.6. Respiratory royalty rate

Chapter 4 – Main Respiratory Agreements and Negotiators

4.1. introduction

4.2. Most active in respiratory partnership

4.3. List of the most active negotiators in Respiratory

4.4. Best Respiratory Deals by Value

Chapter 5 – Directory of respiratory contractual documents

5.1. introduction

5.2. Respiratory partnership agreements when the contractual document is available

Chapter 6 – Respiratory transactions by therapeutic target

6.1. introduction

6.2. Offers by respiratory therapeutic target

Appendices

Annex 1 – Directory of Respiratory offers by company AZ 2010 to 2021

Appendix 2 – Directory of Respiratory transactions by type of transaction 2010 to 2021

Appendix 3 – Directory of Respiratory offers by stage of development 2010 to 2021

Annex 4 – Directory of Respiratory offers by type of technology 2010 to 2021

Companies cited

• Alnylam Pharmaceuticals

• Vortran Medical

• Sichuan University

• Lung and Blood Institute

• Food and Drug Administration (FDA)

• Bill and Melinda Gates Foundation

• Zhejiang Medicine

• Jubilant Drax Picture

• Enzymatic science

• Altavant Sciences

• Biostar Pharmaceuticals

• Scholarly rock

• Therapeutic Monopar

• Wockhardt

• Innovare

• Cellularity

• Highmark Blue Shield

• Highmark Health

• Glenmark Pharmaceuticals

• 4D Pharma

• BES Pharma

• IR Pharma

• IS Pharmaceutical

• Walmart

• Sanovas

• Amyndas Pharmaceuticals

• Therapeutic Tunitas

• Innovata HK

• Medidata solutions

• healthcare advocate

• Innovate in the UK

• Sarcoidosis Research Foundation

• Simulation More

• Innovative Genomics Initiative (IGI)

• Innovative Medicines Initiative (IMI)

• Laboratory Society of America

• Novavax

• Dynavax Technologies

• Pharmaxis

• Beetle genomics

• Punjab Province

For more information about this report, visit https://www.researchandmarkets.com/r/nmgjn9